The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2007Validation of Targets of Small Molecules that Ameliorate Alpha-synuclein Neurotoxicity
Objective/Rationale:
Using high-throughput screening, we have identified a small-molecule compound that rescues toxicity in a yeast model of Parkinson’s Disease and in mammalian neurons. This compound... -
Target Validation, 2007PGC-1 Alpha as a Neuroprotective Target in Parkinson’s Disease
Objective/Rationale:
Many treatments exist that can help to treat the symptoms of Parkinson's disease. But despite these "Symptoms & Side Effects" treatments, the disease continues to progress, with... -
Target Validation, 2007Validation of VPS41, a protein involved in lysosomal trafficking, as a target for Parkinson disease therapy
Objective/Rationale:
Two years ago, in an MJFF-funded search for proteins that are neuroprotective in a simple worm model of PD, the most promising target to emerge was VPS41, believed to be involved... -
Target Validation, 2007Validation of Cathepsin D as a target for Parkinson’s disease therapy
Objective/Rationale:
Cathepsin D is a lysosomal protease important for clearance of long-lived proteins. Alpha-synuclein aggregation is a cardinal pathologic feature of PD. Alpha-synuclein gene... -
Rapid Response Innovation Awards, 2007Does Sporadic Parkinson's Disease Begin in the Enteric Nervous System?
Objective/Rationale:
Although the cause(s) of sporadic Parkinson's disease are still unknown, recent studies indicate the disease-related destruction is highly specific and involves a few nerve cell... -
Novel Approaches to Drug Discovery for Parkinson's Disease, 2007Osteopontin Gene Therapy as a Neuroprotective Treatment for Parkinson's Disease
Objective/Rationale:
Current approaches aimed at slowing or stopping the progression of Parkinson’s disease (PD) have failed due to primarily focusing on targeting specific points on the cell death...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.